Objectives: We sought to identify features in routine evaluation of pre-hematopoietic cell transplantation (HCT) bone marrow samples from patients with acute myeloid leukemia (AML) that influenced patient outcome.
Allogeneic hematopoietic cell transplantation (HCT) is a standard therapeutic modality for patients with acute myeloid leukemia (AML).
1,2 Within 30 days prior to initiation of conditioning for HCT, a bone marrow (BM) biopsy is typically performed to assess the status of disease, since achieving complete remission (CR) is a major factor associated with favorable overall survival in AML. [3] [4] [5] While a number of studies have examined the outcome in patients with active AML, 6-9 myelodysplastic syndrome (MDS), 10 or leukemia-associated cytogenetic abnormalities 11, 12 at the time of HCT, there are no clear guidelines as to the role of findings in the pre-HCT BM sample in determining whether to perform HCT. Few studies have directly examined the association between CR immediately prior to HCT and post-HCT outcome. 13 Minimal residual disease (MRD) determination for AML by flow cytometry has an emerging and important role in risk stratification prior to HCT. 14, 15 However, these techniques are not feasible at most centers, have not been standardized as of yet, and may not be applicable to all patients. 16, 17 Molecular genetic techniques also can be used to assess for MRD in AML prior to HCT, but the genetic and clonal heterogeneity of AML is challenging for the development of standardized mutational MRD assays.
prior to undergoing HCT and identified features that influenced subsequent post-HCT outcomes.
Materials and Methods
We performed a retrospective review of clinicopathologic data for all adult patients who underwent allogeneic HCT after conventional induction chemotherapy for AML at a single institution (Massachusetts General Hospital) between October 30, 2002 , and November 15, 2013, to identify cases with a BM sample taken after induction chemotherapy and prior to HCT (pre-HCT BM). Patients who received any antileukemia therapy after the pre-HCT BM sample and before the HCT or who had received myeloid growth factors within 7 days prior to the pre-HCT sample were excluded. This study was approved by the Partners Healthcare Institutional Review Board.
Data evaluated at the time of AML diagnosis included patient age, sex, history of prior cytotoxic therapy or antecedent myeloid neoplasm, AML karyotype, and NPM1 and FLT3 mutational status if performed. The cases were riskstratified by karyotype according to the United Kingdom Medical Research Council (UKMRC) system. 19 Complete remission (CR) was defined using the standard criteria of less than 5% blasts in the BM aspirate and absence of peripheral blood blasts (not attributable to marrow regeneration) upon count recovery following one or two courses of induction chemotherapy. 5 Some patients had achieved CR prior to the pre-hematopoietic cell transplant (HCT) BM sample, and in these patients, continued CR was defined as less than 5% blasts in the BM aspirate and the absence of peripheral blood blasts. A subset of the latter patients had received consolidation chemotherapy after achieving CR and prior to the pre-HCT marrow sample; consolidation treatment was not included as a variable in the outcome analysis since the types and duration of therapies were highly variable.
The following morphologic features were assessed in the pre-HCT BM sample: cellularity, myeloblast percentage in the aspirate smear, presence of more than 10% dysplasia in each hematopoietic lineage, and any increased or clustered blasts in the core biopsy specimen (more than three cells away from bone trabeculae). Blasts in the core biopsy specimen were identified on routine histology and confirmed by the use of CD34 and/or CD117 immunohistochemistry. Myeloblasts and normal B-cell precursors (hematogones) as a percentage of all events assessed by BM aspirate flow cytometry were also recorded. Bone marrow karyotype, including the presence and percentage of any abnormal leukemia-associated metaphases, was recorded. Peripheral blood (PB) counts and PB blast percentage (if any blasts were present) were also recorded at the time of the pre-HCT BM. Clinical characteristics recorded at the time of HCT included patient age, preparative conditioning regimen, hematopoietic stem cell donor type, and time between the pre-HCT BM and the stem cell infusion (HCT day 0).
Fisher exact test and Mann-Whitney test were used to evaluate differences between patient groups. The primary outcome measure was leukemia-free survival (LFS), defined as time from HCT day 0 to documented relapsed leukemia or death from any cause. An additional outcome measure was overall survival (OS), defined as time from HCT day 0 to death from any cause. The methods of Kaplan-Meier and log-rank test were used to compare LFS and OS between groups. Independent variables predicting LFS and OS were evaluated in a multivariable model using Cox regression analysis. All two-sided P values less than .05 were considered statistically significant. Prism 4.0 (GraphPad Software, La Jolla, CA) and XLSTAT (Addinsoft, New York, NY) were used for statistical analyses.
Results

Patient Characteristics
We identified 140 patients with AML who had received induction chemotherapy followed by HCT and for whom a pre-HCT BM biopsy sample was available. Patient characteristics are summarized in Table 1 . The median patient age at the time of diagnosis was 56 years (range, 19-76 years) and at the time of HCT was 56.5 years (range, 19-76 years). The median interval between diagnosis and HCT was 3 months (range, 2-106 months; interquartile range, 2 months). Most patients (116/140, 83%) had de novo AML, and most harbored an intermediate-risk karyotype (99/140, 71%). FLT3 and NPM1 mutation status was available in a subset of patients (Table 1) . Overall, 51 (36%) of 140 patients proceeded to transplant directly after induction chemotherapy, with the BM biopsy for CR assessment following induction therapy serving as the pre-HCT sample. Sixty-three (45%) of 140 achieved CR after induction therapy but had a longer interval between end of induction and HCT, such that an additional dedicated pre-HCT biopsy was performed prior to the HCT. The remaining 26 (19%) of 140 patients had relapsed or refractory disease and had received additional chemotherapy prior to HCT but before pre-HCT BM biopsy.
Clinicopathologic Findings in the Pre-HCT Bone Marrow Sample interquartile range, 16 days). The PB counts at the time of the pre-HCT BM and the pathologic and cytogenetic findings in the pre-HCT BM are summarized in Table 2 .
Overall, 24 (17%) patients had persistent leukemia in the pre-HCT BM according to standard criteria of 5% or more blasts in the BM aspirate or unexplained PB blasts; these included 23 with 5% or more BM blasts (range, 5%-68%; median, 10%) and one with 18% PB blasts but only 4% BM blasts. Among these 24 cases, 18 represented persistent/refractory disease without achievement of CR after induction, and six represented relapsing disease after documented CR in a prior BM sample Image 1 . Five of these cases with persistent or relapsed disease in the BM aspirate also had an abnormal leukemia-associated BM karyotype. Despite the presence of persistent or recurrent disease, these patients were treated with HCT without additional therapy after the pre-HCT BM evaluation, typically because myeloablative conditioning was planned shortly after the pre-HCT BM or because the disease was refractory to two or more courses of induction chemotherapy.
An additional 14 cases showed other morphologic or karyotypic evidence of recurrent or residual disease that did not meet BM aspirate blast count criteria for relapse (Table 2) . In five cases, clusters of blasts were seen in the BM biopsy specimen (either as a single focus or as multiple small foci away from bone trabeculae) (Image 1). In four of these cases, the blast clusters were highlighted by CD34 (Image 1, inset) and/or (for cases with CD34-negative blasts) CD117 immunohistochemistry, while in one case, the blast clusters were absent on deeper tissue levels. The BM karyotype also showed leukemia-associated metaphases in one of the cases with clustered BM blasts. Two additional cases had sheets of necrotic blasts in the BM biopsy specimen. The seven BM samples with these abnormal BM biopsy findings were all reported as being suspicious for residual/recurrent disease or as showing abnormal findings of uncertain significance, but the patients proceeded to HCT 14 to 29 days after the pre-HCT biopsy without receiving additional therapy. Another seven cases did not show morphologic evidence of leukemia in the pre-HCT BM biopsy specimen or aspirate, but they harbored leukemia-associated karyotype abnormalities. In all cases, the observed karyotype abnormalities were the same as those seen at diagnosis, with a range of one to nine abnormal metaphases (median, seven) out of 20. The original AML karyotypes in these seven cases were high risk in four cases (three with complex karyotypes and one with del(7q)) and in the other three cases showed single abnormalities (t(3;21), trisomy 8, and t(1;14)). Dysplastic changes involving more than 10% of cells were commonly seen in the erythroid lineage (88/127 cases, 69%) and were seen less frequently in the myeloid and megakaryocytic lineages in the pre-HCT BM samples (Table 2) . Regarding flow cytometry findings, there was one case with 10% blasts by flow cytometry and only 1% blasts in the BM aspirate, but this case also had abnormal leukemia-associated metaphases on karyotype; flow cytometry did not identify any additional cases with 5% or more blasts that were not also detected by manual count of the BM aspirate smear.
Associations With Patient Outcomes
The median follow-up time for surviving patients was 55.3 months (range, 11-144.5 months) after HCT. The median OS after HCT of the entire cohort was 22.7 months, and the median LFS after HCT was 17.1 months. Univariate analysis of factors influencing LFS is shown in Table 3 . Patients with prior relapsed AML had shorter LFS than patients undergoing HCT for nonrelapsed AML (median, 5.9 vs 21.5 months; P ¼ .015). Additional patient-related and clinical factors that were significantly associated with shorter LFS after HCT included older age, UKMRC adverse karyotype, use of an alternate (cord blood, mismatched unrelated, or haploidentical) donor, and reduced intensity conditioning.
We next explored pathologic findings in the pre-HCT sample that were associated with shorter LFS after HCT. There was no association of LFS with more than 10% dysplasia in any lineage, marrow cellularity, or hematogone percentage by flow cytometry (Table 3 ). The 24 patients with persistent leukemia in the pre-HCT BM by standard criteria of 5% or more blasts in the BM aspirate or increased blasts in the PB had significantly shorter LFS after HCT compared with patients who had no increased blasts in the PB or BM (median, 10.6 vs 21.5 months; P ¼ .04). The LFS of the 14 patients with persistent/relapsed disease based on other evidence of residual disease in the pre-HCT BM sample (findings in the core biopsy specimen or karyotype) was also markedly shortened (median, 2.4 months). We therefore defined the residual leukemia (RL) group for subsequent analyses as the 38 patients with pre-HCT sample evidence of increased blasts in the BM aspirate or blood, clustered or necrotic blasts in the biopsy specimen, or an abnormal leukemia-associated karyotype. Patients with RL had significantly shorter LFS compared with patients with no morphologic or karyotypic evidence of RL (median, 7.1 vs 28.3 months; P < .0001) Figure 1A . The LFS of the 14 patients with RL based on BM biopsy or karyotype findings was actually borderline shorter than the 24 patients with increased marrow/blood blasts in the pre-HCT BM aspirate (P ¼ .06; Figure 1B ).
We then performed subgroup analysis to determine the influence of RL of any type (n ¼ 38) in the pre-HCT sample in defined patient groups. The presence of RL in the pre-HCT sample was strongly associated with LFS in patients with UKRMC favorable-or intermediate-risk karyotype (median, 8.6 vs 41.6 months; P ¼ .001), while it was less strongly associated with LFS in patients with UKMRC adverse-risk karyotype (median, 5.2 vs 13.5 months RL; P ¼ .04) Figure 2A and Figure 2B . There was no significant impact of RL on the LFS of patients with AML after MDS, chronic myelomonocytic leukemia (CMML), or myeloproliferative neoplasm (MPN) (median, 8.1 vs 8.7 months; P ¼ .46) or on patients with prior relapsed disease (median, 8.1 vs 5.5 months; P ¼ .83). The presence of RL in the pre-HCT sample was associated with shorter LFS after both myeloablative (median, 11.2 vs 42.1 months; P ¼ .0003) and reduced-intensity conditioning (median, 3.6 vs 13.3 months; P ¼ .002) Figure 2C and Figure 2D and using both matched related/unrelated donors (median, 9.6 vs 28.3 months; P ¼ .001) and alternative donor sources (median, 2.6 vs 12.4 months; P ¼ .002) Figure 2E and Figure 2F . Among the patients with RL, there was no significant difference in LFS based on whether the RL represented persistent disease after induction chemotherapy or Figure 1 Residual leukemia (RL) in the pre-hematopoietic cell transplantation (HCT) bone marrow (BM) evaluation adversely affects clinical outcome. A, Cases with any RL identified in the pre-HCT aspirate, peripheral blood, biopsy specimen, or karyotype (n ¼ 38) have shorter leukemia-free survival (LFS) than patients without RL (n ¼ 102) (P < .0001). B, The LFS in patients where RL is manifested by increased blasts in the biopsy or leukemia-associated metaphases on karyotype (n ¼ 14) is borderline shorter than that of patients with RL established by the standard criteria of increased blasts in the BM aspirate or blood (n ¼ 24) (P ¼ .06). B, Among patients with high-risk karyotype acute myeloid leukemia, LFS was shorter in patients with RL (n ¼ 12) than in patients without RL (n ¼ 25, P ¼ .04). C, In patients undergoing myeloablative HCT, those with RL (n ¼ 20) had shorter LFS than those without RL (n ¼ 50, P ¼ .0003). D, In patients undergoing nonmyeloablative/reduced-intensity HCT, those with RL (n ¼ 18) had shorter LFS than those without RL (n ¼ 52, P ¼ .0003). E, In patients receiving a graft from a matched (related or unrelated) donor, shorter LFS was seen in patients with RL (n ¼ 31) than in those without RL (n ¼ 88, P ¼ .001). F, In patients receiving a mismatched or cord blood (alternative) graft, shorter LFS was seen in patients with RL (n ¼ 7) than in those without RL (n ¼ 14, P ¼ .002).
relapsed disease after a prior documented CR (median, 8.9 vs 2.8 months; P ¼ .38). There was also no difference in LFS in patients with RL and 10% or more BM aspirate blasts vs those with RL and less than 10% BM aspirate blasts (median, 7.7 vs 12.3 months; P ¼ .67).
Results of stepwise multivariable analysis (considering all factors significant to P < .15 in the univariate analysis) for LFS and OS are shown in Table 4 . In the final models, the presence of RL in the pre-HCT BM (in the aspirate, in the BM biopsy specimen , or by karyotype), prior relapse of AML, age, high-risk UKMRC karyotype, and alternate donor source were each independently associated with adverse impact on both LFS and OS.
Discussion
We examined the impact of morphologic and cytogenetic findings in pretransplant BM samples on clinical outcomes of patients with AML undergoing allogeneic HCT. Retrospective studies in BM transplantation are challenging, as many variables that may affect outcome must be isolated, and the decision to undergo HCT is highly individualized. The decision to proceed with HCT depends on a combination of factors, including patient characteristics, disease characteristics, and donor availability; treating physicians must weigh each of these factors in determining eligibility. 20, 21 Important patient characteristics include age, performance status, and comorbidities. Disease-specific characteristics include those defined by the World Health Organization classification 22 and other consensus bodies, 23 which categorize AML by cytogenetic and molecular genetic risk groups, morphology, and disease history. The decision to employ HCT is also influenced by available allogeneic stem cell sources, 24 the tolerability of myeloablative vs reduced-intensity conditioning for individual patients, the relative outcomes based on molecular and cytogenetic disease characteristics, and the disease status prior to HCT. Few studies in the pathology literature have specifically studied the impact of routinely obtained histopathologic findings in the BM sample taken prior to HCT on post-HCT outcome in AML. Lee et al 13 showed that higher blast counts in pre-HCT BM aspirates from patients with AML had an adverse impact on posttransplant prognosis. We retrospectively evaluated pre-HCT BM samples from patients with AML at our institution over a 12-year period to determine which factors were associated with post-HCT outcomes and could potentially be used to guide the therapeutic decisions. Although AML subtypes and HCT conditioning regimens in our cohort were diverse, they reflected a typical population of patients with AML seen and treated at transplant centers in the United States, and all were initially treated with standard induction chemotherapy. We identified evidence of RL in 27% of pre-HCT BM samples. In most cases, this manifested as overtly relapsed or refractory disease, with 5% or more blasts in the BM aspirate or PB. However, we also identified cases with clusters of blasts or, in rare cases, sheets of necrotic blasts in the core biopsy specimen and cases with abnormal metaphases on karyotype that reflected the genetic abnormalities in the original AML, despite less than 5% blasts in the aspirate smear and no circulating blasts. BM necrosis is an uncommon but recognized manifestation of leukemia, both at presentation 25 and relapse. [26] [27] [28] Necrotic blasts may not be readily evident in the aspirate smear. 29, 30 Surface antigen expression on necrotic blasts can remain intact in trephine sections and detectable by immunohistochemistry. 31 Although associated with poor outcome in our study, the small number of cases with necrotic marrow makes it difficult to draw definitive conclusions as to the significance of this finding. Much of the predictive power of RL in our study was due to the contribution of the BM biopsy and karyotype findings. Because there is somewhat conflicting literature on the importance of the pre-HCT blast count on prognosis after HCT, 32 our study further highlights the continued importance of identifying these additional manifestations of RL that do not rely on the aspirate smear. Although we did not perform immunohistochemistry on the two cases in our series with cellular necrosis, CD34 and CD117 immunohistochemistry did facilitate confirmation of four cases with clustered blasts seen on routine histology of the BM core biopsy specimen. According to our definition of RL, which includes increased blasts in the BM aspirate or blood, clustered blasts or sheets of necrotic blasts in the BM biopsy specimen, and/or leukemic metaphases on karyotype, we found that RL was associated with markedly shortened LFS and OS after HCT. This effect was independent of other patient-and leukemia-specific features such as karyotypic risk group, age, and HCT source and conditioning regimen. At our institution, we do not routinely perform immunostains on pre-HCT BM core/trephine biopsy specimens. The immunophenotypic features of AML can be variable, with a substantial subset of CD34-negative leukemic blasts and changes in antigenicity after treatment. CD117 stains marrow elements besides myeloid blasts, including erythroid precursors, promyelocytes, and mast cells. Thus, interpretation of the CD117 stain will be difficult when the differential diagnosis of clustered blasts includes nonneoplastic regenerative erythroid precursors. For these reasons, the use of upfront screening of pre-HCT BM core biopsy specimens with immunostains may be misleading, and in this study, we only used these stains to confirm a morphologic suspicion of AML blasts in the biopsy specimen.
The prognostic impact of RL in the pre-HCT BM sample appeared to differ depending on disease-specific features. Among patients with favorable-or intermediate-risk karyotypes, the identification of RL was strongly associated with poor outcome after HCT. In contrast, the outcomes for highrisk karyotype AML or previously relapsed AML were poor irrespective of whether RL was identified immediately prior to HCT. This likely reflects the widespread genetic alterations in complex karyotype AML compared with de novo disease, which may predispose to relapse after HCT, even in the absence of overt morphologically recognizable RL prior to HCT. 33 Although background morphologic dysplasia could suggest a prior myelodysplastic syndrome, which might also be expected to confer a poor prognosis, we did not find any prognostic impact of the presence of morphologic dysplasia in the pre-HCT BM on outcome after HCT. Dysplastic changes were frequently present in cases with RL but were also seen (particularly in the erythroid lineage) in a high proportion of the cases without evidence of RL, and these findings were not associated with adverse outcome. This may relate to the occurrence of reactive dyspoietic changes in recovering marrow following chemotherapy that are difficult to distinguish from dysplasia due to a persistent neoplastic clone. 34 However, we did find that abnormal leukemia-associated metaphases prior to HCT were associated with adverse outcome after HCT, even when not accompanied by increased blasts. We also assessed blast and hematogone percentage by flow cytometry on BM aspirate material. Although the presence of hematogones in patients with AML in remission has been associated with favorable outcome, 35 in our cohort, we did not find an association with the presence of hematogones in the pre-HCT BM and outcome after HCT. Flow cytometry did identify a subset of patients with increased (!5%) myeloblasts in the pre-HCT sample, but all of these patients also met criteria for RL based on the BM aspirate blast percentage. In specialized centers and in the research setting, detailed flow cytometry blast immunophenotyping can identify very small levels of AML, and the presence of such MRD after induction chemotherapy has been associated with worse outcomes. [14] [15] [16] [17] 36 Such sensitive assays are likely to strengthen risk stratification in the near future. Indeed, Inaba et al 32 clearly demonstrated the prognostic significance and sensitivity of flow cytometry-based MRD testing of BM samples following therapy for subtypes of AML. However, flow cytometry detection of MRD in AML requires a specialized, validated technique that is not available at most centers. 37, 38 In addition, not all AML blasts display a leukemia-specific phenotype amenable to distinction from nonneoplastic blasts by flow cytometry. 18 Similarly, next-generation sequencing has been employed to detect low levels of residual AML in specific AML subtypes, 39 particularly reverse transcription polymerase chain reaction detection of NPM1 16 as well as
DNMT3A
. 40 Such testing is not available for clinical application in most centers. Moreover, it remains to be seen whether sensitive methods of MRD detection can be applied more widely to AML harboring other less frequent mutations and whether this would have the same prognostic implications. 18, 41 Results of mutation detection may be difficult to interpret given the occurrence of AML-type mutations in healthy older adults and the long-term persistence of some AML-associated mutations in patients in apparent remission. 42 At the current time in most centers, the standard diagnostic testing for RL remains as blast enumeration in the blood, aspirate smear, and core biopsy specimen and BM karyotype.
The results of our current study suggest that information from these readily available diagnostic tests are strongly and independently correlated with outcome after HCT and can help inform the decision as to whether to proceed to transplant if evidence of recurrent or residual disease is found.
In conclusion, the results of our study validate the role of routine BM sampling prior to allogeneic HCT to identify RL. The presence of RL, defined by increased blasts or abnormal metaphases, prior to HCT is associated with a high likelihood of relapse and short survival following HCT. In particular, RL predicts a very poor outcome in patients undergoing HCT with alternate donors and a relatively poor outcome in patients with favorable-or intermediate-risk karyotype AML. Importantly, we found that the identification of RL should not only rely on the aspirate smear and PB blast enumeration but also incorporate findings in the core biopsy specimen and BM karyotype. As our study was retrospective in nature, we could not determine if additional treatment of patients with RL prior to HCT would improve outcomes. Future prospective studies could help address this question by examining a potential role of additional cytotoxic therapy pre-HCT and/or immunomodulatory therapies post-HCT in patients with RL identified prior to HCT.
